Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a stomach tuck reverse fatty liver?

NCT ID NCT06138821

Recruiting now Disease control Sponsor: Pichamol Jirapinyo, MD, MPH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a minimally invasive procedure called endoscopic sleeve gastroplasty (ESG), which reduces stomach size by 70%, can help reverse fatty liver disease (MASH) in people with obesity. Researchers will compare ESG plus lifestyle changes to lifestyle changes alone in 132 participants. The main goal is to see if MASH resolves without worsening liver scarring after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

endoscopic sleeve gastroplasty (a stomach-reducing procedure using an endoscopic suturing device)

What this could lead to

If it works, this could offer a less invasive alternative to surgery for treating fatty liver disease (MASH) in people with obesity.

What could go wrong

This is a relatively early trial with 132 participants, so results may not apply to everyone. The procedure carries risks like bleeding or infection, and weight regain is possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver diabetes mellitus fatty liver disease fibrotic liver disease Insulin Resistance liver disorder metabolic disease metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES DIABETES MELLITUS (TYPE 2) INSULIN RESISTANCE INSULIN SENSITIVITY INSULIN SENSITIVITY/RESISTANCE LIVER DISEASES LIVER FAT LIVER FIBROSIS MASH MASLD METABOLIC DISEASE METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS NASH WITH FIBROSIS NON ALCOHOLIC FATTY LIVER NON-ALCOHOLIC FATTY LIVER DISEASE NON-ALCOHOLIC STEATOHEPATITIS OBESITY WEIGHT LOSS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • West Virginia University

    RECRUITING

    Morgantown, West Virginia, 26506, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••